Oncotelic Therapeutics (OTLC) CBO granted 1,500 high-leverage RSUs
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Oncotelic Therapeutics CBO Saund Saran received a grant of 1,500 restricted stock units on July 10, 2026. Each RSU represents a contingent right to one share of Series A Convertible Preferred Stock, which is convertible into 1,000 common shares, for up to 1,500,000 common shares if fully vested and converted. The RSUs are subject to performance and time-based vesting tied to an uplisting of the company’s common stock to a national securities exchange and continued service requirements.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Saund Saran
Role
CBO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted stock Units | 1,500 | $0.00 | -- |
Holdings After Transaction:
Restricted stock Units — 1,500 shares (Direct)
Footnotes (1)
- On July 10, 2026, the reporting person was granted 1,500 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share. The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.
Key Figures
RSUs granted: 1,500 RSUs
Underlying preferred shares: 1,500 shares
Common shares per preferred share: 1,000 shares
+3 more
6 metrics
RSUs granted
1,500 RSUs
Restricted stock units granted to CBO Saund Saran on July 10, 2026
Underlying preferred shares
1,500 shares
Each RSU represents one share of Series A Convertible Preferred Stock
Common shares per preferred share
1,000 shares
Each Series A Convertible Preferred Stock share is convertible into 1,000 common shares
Potential common shares on full conversion
1,500,000 shares
If all 1,500 RSUs vest, settle into preferred stock, and are fully converted
Vesting performance deadline
June 30, 2027
Uplisting to a national securities exchange must occur by this date unless extended by the Board
Par value of Series A Convertible Preferred Stock
$0.01
Par value per share of the issuer's Series A Convertible Preferred Stock
Key Terms
Restricted stock units, Series A Convertible Preferred Stock, performance and time-based vesting, uplisting, +1 more
5 terms
Restricted stock units financial
"the reporting person was granted 1,500 restricted stock units ("RSUs"), subject to performance"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Series A Convertible Preferred Stock financial
"one share of the issuer's Series A Convertible Preferred Stock, par value $0.01"
Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.
performance and time-based vesting financial
"granted 1,500 restricted stock units ("RSUs"), subject to performance and time-based vesting"
uplisting financial
"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock"
Uplisting occurs when a company's stock moves from a less regulated, smaller exchange to a more established and widely recognized one. This transition can make the stock more accessible and attractive to a broader range of investors, potentially increasing its value and trading volume. For investors, uplisting often signals growth and stability, which can influence confidence and trading decisions.
national securities exchange regulatory
"uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027"
A national securities exchange is a regulated marketplace where buyers and sellers trade stocks, bonds and other securities and where companies meet requirements to have their shares available to the public. It matters to investors because the exchange enforces rules, provides transparent prices and a steady flow of buyers and sellers—like a supervised marketplace that helps ensure fair pricing, easier buying and selling, and basic investor protections.
FAQ
What insider transaction did Oncotelic Therapeutics (OTLC) report for CBO Saund Saran?
Oncotelic Therapeutics reported that CBO Saund Saran was granted 1,500 restricted stock units (RSUs) on July 10, 2026. These RSUs are a form of equity compensation that may settle in Series A Convertible Preferred Stock if vesting conditions are met.
What are the vesting conditions for Saund Saran’s 1,500 RSUs at Oncotelic (OTLC)?
The 1,500 RSUs will vest only upon achievement of an uplisting of Oncotelic’s common stock to a national securities exchange on or before June 30, 2027 (or a later Board-approved date), plus six months of continued service after the uplisting.
Into what securities can Saund Saran’s RSUs at Oncotelic (OTLC) ultimately convert?
Each RSU can settle into one share of Series A Convertible Preferred Stock, and each such preferred share is convertible into 1,000 shares of common stock. If all 1,500 RSUs vest and convert, they would represent up to 1,500,000 common shares.
Was Saund Saran’s Form 4 transaction in OTLC stock a market buy or sell?
No market buy or sell occurred. The Form 4 reports a grant/award acquisition (code A) of 1,500 RSUs as compensation. There were no open-market purchases or sales of Oncotelic common stock disclosed in this transaction.
How many RSUs does Saund Saran hold after this Oncotelic (OTLC) grant?
After the reported transaction, Saund Saran holds 1,500 restricted stock units directly. These units are subject to the specified performance and time-based vesting conditions before they can settle into Series A Convertible Preferred Stock and ultimately common shares.
What key date is associated with the performance condition on Saund Saran’s OTLC RSUs?
The performance condition requires an uplisting to a national securities exchange on or before June 30, 2027, unless the Board approves a later date. Vesting also depends on Saund Saran’s continued service for six months following that uplisting.